Currently, the treatment of advanced NSCLC relies on molecular testing for predictive biomarkers, including oncogenic drivers, to determine eligibility for targeted therapies such as those for EGFR, ALK, ROS1, BRAF, HER2, MET, RET, or KRASG12C. Here, BRAF is linked to non-small cell lung carcinoma.